[go: up one dir, main page]

AU2002360620A1 - Therapeutic compounds for treating dyslipidemic conditions - Google Patents

Therapeutic compounds for treating dyslipidemic conditions Download PDF

Info

Publication number
AU2002360620A1
AU2002360620A1 AU2002360620A AU2002360620A AU2002360620A1 AU 2002360620 A1 AU2002360620 A1 AU 2002360620A1 AU 2002360620 A AU2002360620 A AU 2002360620A AU 2002360620 A AU2002360620 A AU 2002360620A AU 2002360620 A1 AU2002360620 A1 AU 2002360620A1
Authority
AU
Australia
Prior art keywords
group
substituted
occurrence
unsubstituted
mono
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002360620A
Other languages
English (en)
Inventor
Alan D Adams
Ahren Green
Shaei Y Huang
A Brian Jones
Bruno Tse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU2002360620A1 publication Critical patent/AU2002360620A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
AU2002360620A 2001-12-20 2002-12-16 Therapeutic compounds for treating dyslipidemic conditions Abandoned AU2002360620A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34255601P 2001-12-20 2001-12-20
US60/342,556 2001-12-20
PCT/US2002/040236 WO2003053352A2 (fr) 2001-12-20 2002-12-16 Composes therapeutiques destines au traitement d'etats dyslipidemiques

Publications (1)

Publication Number Publication Date
AU2002360620A1 true AU2002360620A1 (en) 2003-07-09

Family

ID=23342338

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002360620A Abandoned AU2002360620A1 (en) 2001-12-20 2002-12-16 Therapeutic compounds for treating dyslipidemic conditions

Country Status (5)

Country Link
EP (1) EP1458694A4 (fr)
JP (1) JP2005519042A (fr)
AU (1) AU2002360620A1 (fr)
CA (1) CA2470591A1 (fr)
WO (1) WO2003053352A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2064701A (en) * 1999-12-13 2001-06-18 Merck & Co., Inc. Method for the prevention and/or treatment of atherosclerosis
AU2003256655A1 (en) 2002-07-25 2004-02-16 Merck And Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
KR101021828B1 (ko) 2004-10-27 2011-03-17 다이이찌 산쿄 가부시키가이샤 2 이상의 치환기를 갖는 벤젠 화합물
RU2007126842A (ru) * 2004-12-14 2009-01-27 Санофи-Авентис Дойчланд Гмбх (De) Применение замещенных производных циклопропановой кислоты для получения лекарственных средств для лечения метаболического синдрома
WO2012027331A1 (fr) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions et procédés pour traiter ou prévenir un syndrome métabolique et des maladies et troubles associés
KR101901741B1 (ko) 2010-09-07 2018-10-01 서울대학교산학협력단 세스터터핀 화합물 및 이들 물질의 용도

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002503203A (ja) * 1996-02-02 2002-01-29 メルク エンド カンパニー インコーポレーテッド 抗糖尿病薬及び抗肥満症薬としての複素環誘導体

Also Published As

Publication number Publication date
EP1458694A2 (fr) 2004-09-22
CA2470591A1 (fr) 2003-07-03
WO2003053352A2 (fr) 2003-07-03
EP1458694A4 (fr) 2005-12-14
JP2005519042A (ja) 2005-06-30
WO2003053352A3 (fr) 2003-11-20

Similar Documents

Publication Publication Date Title
AU2002251978B2 (en) 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
US6908934B2 (en) Therapeutic compounds for treating dyslipidemic conditions
AU721452B2 (en) Antidiabetic agents
US7125865B2 (en) Therapeutic compounds for treating dyslipidemic conditions
IL104748A (en) Isoxazolyl sulfonamide derivatives and pharmaceutical compositions containing the same
JPWO2008096829A1 (ja) ３環系化合物
CA3059869A1 (fr) Derives d'isoxazole comme agonistes des recepteurs nucleaires et leurs utilisations
EP1448193A1 (fr) Composes therapeutiques pour le traitement d'etats dyslipidemiques
AU2002360620A1 (en) Therapeutic compounds for treating dyslipidemic conditions
AU2006220809B2 (en) Fused aromatic compounds having anti-diabetic activity
US20060178398A1 (en) Therapeutic compounds for treating dyslipidemic conditions
AU2005270201A1 (en) Indoles having anti-diabetic activity
DE102004016845A1 (de) Phenylthioessigsäure-Derivate und ihre Verwendung
JP2976003B2 (ja) ４位置換イソキノロン誘導体
AU2005287215B2 (en) Compounds for the treatment of dyslipidemia and other lipid disorders
US20040266849A1 (en) Therapeutic compounds for treating dyslipidemic conditions
US20050113419A1 (en) Therapeutic compounds for treating dyslipidemic conditions
WO2007081335A1 (fr) Composes therapeutiques pour traiter des troubles dyslipidemiques
KR102883856B1 (ko) 파르네소이드 x 수용체 조정제로서 유용한 치환된 아미드 화합물
CA3129619A1 (fr) Composes d'amides substitues utilises en tant que modulateurs du recepteur x farnesoide
JPH09241206A (ja) リグナン系化合物
CN107098946B (zh) Cetp抑制剂的合成与用途

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application